Bidridistrogene Xeboparvovec
drug drugOn this page
Also known as Scaavrh74.mhck7.hsgcbSRP-9003
Summary
Bidridistrogene Xeboparvovec (CHEMBL4650240) is a phase-3 clinical-stage gene; indicated across 1 condition including limb-girdle muscular dystrophy.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Gene
- Indications: 1 condition
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650240 |
| Name | Bidridistrogene Xeboparvovec |
| Type | Gene |
| Max phase | 3 |
Also known as: Bidridistrogene xeboparvovec, Scaavrh74.mhck7.hsgcb, SRP-9003, BIDRIDISTROGENE XEBOPARVOVEC
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| limb-girdle muscular dystrophy | 3 | MONDO:0016971 | MONDO:0016971 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06246513 | PHASE3 | ACTIVE_NOT_RECRUITING | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 |
| NCT03652259 | PHASE1/PHASE2 | TERMINATED | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) |
| NCT05876780 | PHASE1 | ACTIVE_NOT_RECRUITING | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: limb-girdle muscular dystrophy